NCT07041606 An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation
| NCT ID | NCT07041606 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AstraZeneca |
| Condition | Endometrial Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2025-06-24 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2025-06-24 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Multicenter, observational, prospective study of molecular profiling in advanced and aggressive endometrial cancer patients and 1-st line treatment approaches in Russian Federation
Eligibility Criteria
Inclusion Criteria: 1. Female patients aged ≥ 18 years old; 2. Signed ICF, including consent for archival FFPE tumor tissue block testing; 3. Newly diagnosed, histologically confirmed, advanced (III-IV stage) EC, with the date of diagnosis of histologically confirmed disease within 4 months before inclusion; 4. Endometrioid type G3 or any non-endometrioid histological type of EC (such as serous carcinoma, clear cell carcinoma, mixed carcinoma, undifferentiated and dedifferentiated carcinoma, carcinosarcoma, others); 5. The presence of biopsy or postoperative archival FFPE tumor sample (block); 6. Availability of source medical documentation. Exclusion Criteria: 1\. Patients participating in clinical (interventional) studies since the diagnosis of histologically confirmed, advanced EC.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07041606 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Endometrial Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07041606 currently recruiting?
Yes, NCT07041606 is actively recruiting participants. Contact the research team at information.center@astrazeneca.com for enrollment information.
Where is the NCT07041606 trial being conducted?
This trial is being conducted at Arkhangelsk, Russia, Barnaul, Russia, Chelyabinsk, Russia, Irkutsk, Russia and 11 additional locations.
Who is sponsoring the NCT07041606 clinical trial?
NCT07041606 is sponsored by AstraZeneca. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.